Intensity Therapeutics Announces Reverse Stock Split
Rhea-AI Summary
Intensity Therapeutics (Nasdaq: INTS) announced a 1-for-25 reverse stock split effective 4:01 p.m. ET on February 18, 2026, with post-split trading to begin February 19, 2026 under the existing ticker INTS.
The split reduces outstanding shares from ~63,346,579 to ~2,533,863, adjusts option/warrant conversion terms proportionally, preserves total authorized shares, and provides cash in lieu of fractional shares.
The company said the Reverse Split aims to raise the per-share trading price to regain compliance with Nasdaq’s minimum bid price requirement.
Positive
- Outstanding shares reduced from ~63.35M to ~2.53M
- Post-split trading continues under ticker INTS
Negative
- Reverse split signals prior noncompliance with Nasdaq minimum bid price
- No reduction in total authorized shares; potential dilution remains
News Market Reaction – INTS
On the day this news was published, INTS declined 32.58%, reflecting a significant negative market reaction. Argus tracked a trough of -41.3% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $22.29M at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves: ERNA -3.02%, MBRX -3.23%, MBIO -5.43% down, while LYRA is up 6.06%. Scanner notes 3 of 4 momentum peers moving down, suggesting broader biotech volatility rather than an isolated move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | Brand alignment | Neutral | -1.6% | Saia rebranded its logistics arm as Saia Logistics with no operational changes. |
| Jan 13 | Strategic update | Positive | +1.4% | Highlighted 2025 clinical data, fundraising over $20M, and runway into Q2 2027. |
| Dec 11 | Clinical posters | Positive | +7.3% | Detailed early INVINCIBLE‑4 data and Phase 3 concept at SABCS 2025. |
| Dec 05 | Nasdaq extension | Positive | +10.2% | Received 180‑day extension to regain compliance with $1.00 minimum bid price. |
| Dec 04 | Conference previews | Positive | +13.0% | Announced two upcoming SABCS 2025 presentations on INT230‑6 in breast cancer. |
Recent INTS news tied to clinical progress and Nasdaq compliance has generally seen positive price reactions on the following day.
Over recent months, Intensity Therapeutics news has focused on clinical data and listing compliance. In December 2025, updates on SABCS presentations and the INVINCIBLE-4 program coincided with several double‑digit percentage gains, while a 180‑day Nasdaq bid‑price extension on Dec 5, 2025 also saw a strong positive move. A January 13, 2026 update detailed a 75% disease control rate and runway into Q2 2027, with shares up modestly. Today’s reverse split implements the shareholder‑approved plan to address Nasdaq bid‑price issues highlighted in prior filings.
Market Pulse Summary
The stock dropped -32.6% in the session following this news. The split cuts outstanding shares from about 63.3M to roughly 2.53M without reducing authorized shares, and follows earlier Nasdaq bid‑price extensions. Historical data show positive responses to clinical and compliance news, so a sharp decline could reflect worry about future capital raises or reverse‑split stigma.
Key Terms
reverse stock split financial
cusip financial
stock options financial
warrants financial
convertible securities financial
book-entry form technical
transfer agent financial
AI-generated analysis. Not financial advice.
Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026
The 1-for-25 Reverse Split will automatically convert every twenty-five (25) current shares of the Company's common stock into one (1) share of common stock. No fractional shares will be issued in connection with the Reverse Split. Stockholders who would otherwise hold a fractional share of the Company's common stock following the Reverse Split will receive a cash payment in lieu thereof at a price equal to that fractional share to which the stockholder would otherwise be entitled multiplied by the closing sale price of the common stock on The Nasdaq Capital Market, as adjusted for the Reverse Split, on February 18, 2026.
The Reverse Split will reduce the number of shares of outstanding common stock from approximately 63,346,579 shares, the number of shares outstanding as of February 12, 2026, to approximately 2,533,863 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company's outstanding stock options, warrants, and convertible securities, and to the number of shares issued and issuable under the Company's stock incentive plans.
Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers' particular processes, and will not be required to take any action in connection with the Reverse Split. For those stockholders holding physical stock certificates, the Company's transfer agent, Continental Stock Transfer & Trust, will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable.
About INT230-6
INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity's proprietary DfuseRx℠ technology platform. The drug consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule ("SHAO") that facilitates the dispersion of potent cytotoxic drugs throughout tumors, allowing the active agents to diffuse into cancer cells. These agents remain in the tumor, resulting in a favorable safety profile. In addition to local disease control and direct tumor killing, INT230-6 causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression, which often occurs with systemic chemotherapy.
About Intensity Therapeutics
Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor's dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional immunotherapy. Intensity has completed two clinical studies and enrolled over 200 patients using INT230-6; a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the "INVINCIBLE-2 Study") (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the "INVINCIBLE-3 Study") (NCT06263231), testing INT230-6 as second or third line monotherapy compared to the standard of care ("SOC") with overall survival as an endpoint. Intensity also initiated a Phase 2 study (the "INVINCIBLE-4 Study") (NCT06358573) in collaboration with the Swiss Cancer Group, formerly the Swiss Group for Clinical Cancer Research SAKK, as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. Pathological complete response ("pCR") is the endpoint. For more information about Intensity, including publications, papers and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company's expected future plans, cash runway, development activities, projected milestones, business activities or results. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the initiation, timing, progress and results of future preclinical studies and clinical trials and research and development programs; the need to raise additional funding before the Company can expect to generate any revenues from product sales; plans to develop and commercialize product candidates; the timing or likelihood of regulatory filings and approvals; the ability of the Company's research to generate and advance additional product candidates; the risk that product candidates that appear promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials; the implementation of the Company's business model, strategic plans for the Company's business, product candidates and technology; commercialization, marketing and manufacturing capabilities and strategy; the rate and degree of market acceptance and clinical utility of the Company's system; the Company's competitive position; the Company's intellectual property position; developments and projections relating to the Company's competitors and its industry; the Company's ability to maintain and establish collaborations or obtain additional funding; expectations related to the use of cash and cash equivalents and investments; our potential inability to satisfy the Nasdaq Capital Market's requirements for continued listing and be subject to delisting; estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other risks described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in the Company's subsequent SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor Relations Contact:
Justin Kulik
CORE IR
coreirteam@coreir.com
(516) 222-2560
Media Contact:
Matt Cossel
CORE IR
pr@coreir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-announces-reverse-stock-split-302687690.html
SOURCE Intensity Therapeutics Inc.
FAQ
What is the 1-for-25 reverse stock split for Intensity Therapeutics (INTS) effective February 18, 2026?
Will Intensity Therapeutics (INTS) keep the same ticker and CUSIP after the February 19, 2026 trading adjustment?
Do Intensity Therapeutics (INTS) stock option and warrant terms change after the 1-for-25 reverse split?
